Abstract
This long-term metabolic and hemorheological study investigated the effects of monophasic contraceptive treatment with 30 μg ethinylestradiol/75 μg gestodene in 20 healthy young women. No modifications of arterial blood pressure levels, blood/plasma serum viscosity and erythrocyte deformability were demonstrated during the study. Likewise, α2-macroglobulin serum concentrations and hemostatic parameters (fibrinogen, fibronectin, antithrom-biti III, Von Willebrand factor antigen) remained unchanged in the 2-year follow-up period. Concerning the metabolic action of oral contraception on lipid, lipoprotein and apolipoprotein patterns, no significant variations of high-density lipoprotein (HDL)-, low-density lipoprotein (LDL)-, very low density lipoprotein (VLDL)-cholesterol, triglyceride, non-esterified fatty acids (NEFA), LDL-, HDL-, VLDL-lipoprotein and apolipoprotein A-I, A and B levels werefound throughout the 24 months of treatment with the monophasic pill. No differences for each parameter studied were observed at the end of the study between women treated with oral contraceptives and a matched group of healthy controls. The gestodene/ethinylestradiol monophasic combination may therefore represent an important therapeutic approach in order to avoid metabolic and cardiovascular complications during long-term hormonal contraception.
| Original language | English |
|---|---|
| Pages (from-to) | 5-12 |
| Number of pages | 8 |
| Journal | Gynecological Endocrinology |
| Volume | 10 |
| Issue number | SUPPL. 5 |
| DOIs | |
| Publication status | Published - 1996 |
Fingerprint
Keywords
- Gestodene
- Hemorheology
- Oral Contraceptive
ASJC Scopus subject areas
- Endocrinology
- Endocrinology, Diabetes and Metabolism
- Obstetrics and Gynaecology
Cite this
A long-term study of the hematological and metabolic effects of a low-dose monophasic oral contraceptive containing gestodene. / Solerte, S. B.; Fioravanti, M.; Spinillo, A.; Berard, P.; Severgnini, S.; Ferrari, E.; Guaschino, S.
In: Gynecological Endocrinology, Vol. 10, No. SUPPL. 5, 1996, p. 5-12.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A long-term study of the hematological and metabolic effects of a low-dose monophasic oral contraceptive containing gestodene
AU - Solerte, S. B.
AU - Fioravanti, M.
AU - Spinillo, A.
AU - Berard, P.
AU - Severgnini, S.
AU - Ferrari, E.
AU - Guaschino, S.
PY - 1996
Y1 - 1996
N2 - This long-term metabolic and hemorheological study investigated the effects of monophasic contraceptive treatment with 30 μg ethinylestradiol/75 μg gestodene in 20 healthy young women. No modifications of arterial blood pressure levels, blood/plasma serum viscosity and erythrocyte deformability were demonstrated during the study. Likewise, α2-macroglobulin serum concentrations and hemostatic parameters (fibrinogen, fibronectin, antithrom-biti III, Von Willebrand factor antigen) remained unchanged in the 2-year follow-up period. Concerning the metabolic action of oral contraception on lipid, lipoprotein and apolipoprotein patterns, no significant variations of high-density lipoprotein (HDL)-, low-density lipoprotein (LDL)-, very low density lipoprotein (VLDL)-cholesterol, triglyceride, non-esterified fatty acids (NEFA), LDL-, HDL-, VLDL-lipoprotein and apolipoprotein A-I, A and B levels werefound throughout the 24 months of treatment with the monophasic pill. No differences for each parameter studied were observed at the end of the study between women treated with oral contraceptives and a matched group of healthy controls. The gestodene/ethinylestradiol monophasic combination may therefore represent an important therapeutic approach in order to avoid metabolic and cardiovascular complications during long-term hormonal contraception.
AB - This long-term metabolic and hemorheological study investigated the effects of monophasic contraceptive treatment with 30 μg ethinylestradiol/75 μg gestodene in 20 healthy young women. No modifications of arterial blood pressure levels, blood/plasma serum viscosity and erythrocyte deformability were demonstrated during the study. Likewise, α2-macroglobulin serum concentrations and hemostatic parameters (fibrinogen, fibronectin, antithrom-biti III, Von Willebrand factor antigen) remained unchanged in the 2-year follow-up period. Concerning the metabolic action of oral contraception on lipid, lipoprotein and apolipoprotein patterns, no significant variations of high-density lipoprotein (HDL)-, low-density lipoprotein (LDL)-, very low density lipoprotein (VLDL)-cholesterol, triglyceride, non-esterified fatty acids (NEFA), LDL-, HDL-, VLDL-lipoprotein and apolipoprotein A-I, A and B levels werefound throughout the 24 months of treatment with the monophasic pill. No differences for each parameter studied were observed at the end of the study between women treated with oral contraceptives and a matched group of healthy controls. The gestodene/ethinylestradiol monophasic combination may therefore represent an important therapeutic approach in order to avoid metabolic and cardiovascular complications during long-term hormonal contraception.
KW - Gestodene
KW - Hemorheology
KW - Oral Contraceptive
UR - http://www.scopus.com/inward/record.url?scp=80051927608&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80051927608&partnerID=8YFLogxK
U2 - 10.3109/09513599609049603
DO - 10.3109/09513599609049603
M3 - Article
AN - SCOPUS:80051927608
VL - 10
SP - 5
EP - 12
JO - Gynecological Endocrinology
JF - Gynecological Endocrinology
SN - 0951-3590
IS - SUPPL. 5
ER -